Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

Cherry T. Thomas, Patrick T. Bradshaw, Bradley H Pollock, James E. Montie, Jeremy M G Taylor, Howard D. Thames, Patrick W. McLaughlin, David A. DeBiose, David H. Hussey, Richard L. Wahl

Research output: Contribution to journalReview article

97 Scopus citations

Abstract

Purpose: We evaluated the prognostic significance of indium-111 ( 111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95% confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95% CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95% CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.

Original languageEnglish (US)
Pages (from-to)1715-1721
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy'. Together they form a unique fingerprint.

  • Cite this

    Thomas, C. T., Bradshaw, P. T., Pollock, B. H., Montie, J. E., Taylor, J. M. G., Thames, H. D., McLaughlin, P. W., DeBiose, D. A., Hussey, D. H., & Wahl, R. L. (2003). Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. Journal of Clinical Oncology, 21(9), 1715-1721. https://doi.org/10.1200/JCO.2003.05.138